This publication evaluates the carcinogenic risks to humans posed by the use of four antiretroviral agents, four DNA topoisonmerase II inhibitors used in the treatment of cancer, and an additional three pharmaceutical agents (hydroxyures, phenolphthalein and vitamin K substances).